Molecular Mechanisms of Hematologic Disorders
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 25 January 2026 | Viewed by 84
Special Issue Editor
Interests: hematology; flow cytometry; immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In solid tumors and hematological disorders, the presence of specific molecular alterations confers aggressive disease behavior, drug resistance, and clonal evolution potential. For example, del(17p), with or without TP53 mutations, leads to the loss of p53 tumor suppressor function, promoting genomic instability, impaired DNA repair, and apoptosis resistance, thereby favoring mutagenesis, disease progression, and unresponsiveness to conventional therapies for all tumors. Conversely, there are molecular alterations that can drive and/or characterize certain diseases, such as t(9;22) for chronic myeloid leukemia, t(15;17) for acute promyelocytic leukemia, or BRAF V600E in hairy cell leukemia. Therefore, molecular alterations result in impaired or dysregulated downstream signaling, causing uncontrolled cell proliferation, altered chromatin structure and epigenetic regulation, DNA damage tolerance, resistance to apoptosis, cell adhesion, migration, and angiogenesis. However, the presence of molecular hits can represent an advantage in terms of therapeutic strategies, as molecular alterations can be druggable, leading to the improvement of clinical outcomes.
For these reasons, a deeper understanding of these mechanisms is essential for the development of targeted therapeutic strategies tailored to the genetic and molecular landscapes and to better define the pathogenetic mechanisms underlying hematological diseases and their related prognoses.
The goal of this Special Issue is to provide an overview of and new insights into molecular mechanisms in benign and malignant hematological disorders for a better understanding of the mechanisms by which neoplastic cells could lead to disease development as well as progression and drug resistance. This Special Issue has three main objectives: The first objective is to review the most recent knowledge on molecular mechanisms in hematological disorders, including new methodologies for more specific and sensitive identification in human samples. The second objective is to give new insights into molecular alterations and disease development as well as progression, or drug development. The third objective is to investigate novel molecular mechanisms that could contribute to disease development and progression, and that eventually could be targeted by specific anti-tumor agents.
Dr. Valentina Giudice
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- solid tumors
- hematologic disorders
- hematology
- bone marrow failure
- leukemia
- myeloma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
